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Background/aim: To evaluate the predictive role of the circulating levels of vascular endothelial growth factor (VEGF) in gastric cancer
patients.
Materials and methods: This study is a case-control study. We measured serum VEGF levels of 30 patients aged between 34 and 83 years
with gastric cancer and 30 patients without malignant pathology, operated on for benign pathologies, with ages ranging from 18 to 69.
Results: Serum levels of VEGF were correlated with the tumor type classification (signet cell adenocarcinoma) and the presence of
adjacent tissue invasion. There was also a positive correlation between serum VEGF and carcinoembryonic antigen levels.
Conclusion: In gastric cancer patients, serum VEGF levels may provide additional prognostic information for preoperative evaluation
of invasion and tumor type.
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1. Introduction
Gastric cancer is one of the most common cancers
worldwide, accounting for about 8% of new cancers (1).
The incidence of gastric cancer has declined rapidly over
the past few decades in most parts of the world, but it is
still one of the most common cancer types worldwide
(2). Incidence rates for gastric cancer are highest in East
Asia (China, Japan, and Korea), East Europe, and South
America, and the 5-year survival rate for gastric cancer
is poor. Altogether, gastric cancer still accounts for more
than 10% of cancer deaths worldwide, being the second
most frequent cause of cancer death following lung cancer
(1). The main prognostic factors in gastric cancer are
clinicopathological characteristics of the disease including
tumor size, stage, and grade. There are prognostic models
to predict the outcome of gastric cancer patients (3,4).
However, the prognostic factors do not fully predict
individual clinical outcomes. Better markers are needed
to identify patients with poor prognosis at the time of
diagnosis. Researchers have focused on the potential role
of new biological factors involved in the carcinogenic
process as prognostic markers in patients with gastric
cancer (5).
Angiogenesis is defined as the process of new capillary
formation from preexisting vasculature (6). In regulating
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tumor angiogenesis, the vascular endothelial growth
factor (VEGF) family plays a determinant role. VEGF
induces cell proliferation, differentiation, and migration
of vascular endothelial cells (7). VEGF is also required for
the establishment of vascularization in malignant tumors,
which benefits primary tumor growth and metastasis (8).
Recently, targeting constitutive VEGF and/or its receptors
has become an attractive approach for cancer therapy (9).
In this study, we investigated, in a consecutive series of
30 gastric cancer patients undergoing surgery, the possible
correlation of VEGF with clinicopathological features in
an effort to identify gastric cancer patients with different
prognoses who could benefit from tailored and targeted
treatments.
2. Materials and methods
This prospective study was performed in the Ankara
Numune Research and Training Hospital after the regional
ethics committee approved the project, and written
informed consent was obtained from all patients and
controls before their inclusion. Thirty consecutive patients
with newly diagnosed and histologically confirmed gastric
cancer were included in this study. There were 20 men
and 10 women with a median age of 64.3 (min: 34, max:
83) years. Patients who had a second cancer or received
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chemotherapy, radiotherapy, or blood transfusion before
surgery were excluded from the study. Tumor staging
was based on clinical information, radiologic reports
(chest radiography, abdominal ultrasonography, and
computerized tomography), operative findings, and
pathology reports. The staging was made in accordance
with the TNM staging system for gastric cancer and
TNM staging was done according to the American
Joint Committee on Cancer (AJCC) (10). Tumors were
histologically classified as intestinal or diffuse according to
their Lauren type and were graded as well, moderately, or
poorly differentiated based on the predominant cell type.
The control subjects were 30 healthy volunteers with a
median age of 41.3 (min: 18, max: 69) years and consisted
of 19 men and 11 women. The absence of disease was
confirmed by clinical history, physical examination, and
routine laboratory tests, including liver and renal function
tests.
Five-milliliter venous blood samples were taken from
the 30 healthy volunteers. The gastric cancer patients’
blood samples were taken just before operation. The values
of VEGF, hemoglobin, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), alpha-fetoprotein (AFP),
and carcinoembryonic antigen (CEA) of each patient who
had the diagnosis of gastric cancer were recorded from the
patient’s file. Information about invasion and metastasis
was recorded from the operation notes, and tumor
differentiation, Lauren type, histological tumor type, T
(depth of the tumor), and N (involvement of dissected
lymph nodes) data were taken from pathology results.
VEGF levels were compared with these results.
2.1. Biochemical analysis
The 5-mL blood sample was put in an EDTA-Na tube.
Serum samples were kept at –20 °C for more than 2
weeks after centrifuging for 10 min at 3000 rpm. VEGF
levels from sera were determined with the enzyme-linked
immunosorbent assay method (CytELISA Human VEGF,
CytImmune Science, College Park, MD, USA). The
measuring range for the assay was 40–5000 pg/mL.
2.2. Statistical analysis
Obtained data were evaluated statistically by SPSS 11.0
(SPSS Inc., Chicago, IL, USA). The evaluation between the
control group and the group who had a diagnosis of gastric
cancer was conducted with a Fisher’s exact chi-square
test in terms of age and sex. VEGF levels between the
gastric cancer and control groups were evaluated with a 2
independent-samples t-test. VEGF levels and parameters
that contained 2 varieties were evaluated with a Mann–
Whitney U test. Both nonparametric one-way ANOVA
and the Kruskal–Willis test were applied between groups
that had VEGF levels and 3 varieties or more. The relations
between varieties were evaluated by using the Spearman
correlation test and P < 0.05 was considered statistically
signiﬁcant.

3. Results
In total, 39 patients were men (65%) and 21 patients were
women (35%). In the gastric cancer group, 20 patients
were men (66.7%) and 10 patients were women (33.3%).
In the control group, 19 were men (63.3%) and 11 were
women (36.7%). The mean age in the gastric cancer group
was 64.3 (min: 34, max: 83) years and the mean age in the
control group was 41.3 (min: 18, max: 69) (Table 1).
The mean VEGF value of the gastric cancer patients
was 142 pg/mL (min: 40, max: 542.1), and the mean VEGF
value of the control group was 104 pg/mL (min: 40, max:
542). This difference between the control and the gastric
cancer groups was not statistically significant (P > 0.05)
(Table 1).
The mean hemoglobin value in the gastric cancer group
was 10.453 g/dL (min: 4.2, max: 14.6), the mean AST value
was 29.48 IU/L (min: 12, max: 79), and the mean ALT
value was 25.93 IU/L (min: 3, max: 93).
CEA and AFP levels were obtained from 11 of 30
patients in the gastric cancer group. The mean CEA level
was 714.391 µg/L (min: 1.5, max: 7480), and the mean
AFP value was 15.527 µg/L (min: 1.2, max: 112.2). There
was a significant positive correlation between CEA and
high VEGF levels (P < 0.05). When the relation between
VEGF and CEA was evaluated with Spearman correlation,
the R parameter was found to be 0.80, and this shows a
strong relationship.
The distribution of the tumor types in the pathology
results of 30 patients operated on with gastric cancer
were adenocarcinoma in 24 patients (80%), signet ring
cell adenocarcinoma in 4 patients (13.3%), early gastric
cancer in 1 patient (3.3%), and malignant tumor showing
neuroendocrine differentiation in 1 patient (3.3%). The
mean VEGF levels in signet ring cell adenocarcinoma, early
gastric carcinoma, and well-differentiated neuroendocrine
carcinoma cases were 110, 384, and 40 pg/mL respectively.
This difference in the signet ring cell adenocarcinomas was
statistically significant (P > 0.005) (Table 2).
Table 1. Demographic features.
Gastric cancer group,
n (% or min–max)

Control group,
n (% or min–max)

Male

20 (67%)*

19 (63%)*

Female

10 (33%)*

11 (37%)*

Age

64.3 (34–83)*

41.3 (18–69)*

VEGF levels

142 (40–542.1)*

104 (40–542)*

Sex

*: The differences are not significant (P > 0.05).
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Table 2. The relation between preoperative serum VEGF and clinicopathological parameters in gastric cancer patients.
Number of patients

Serum VEGF (pg/mL)

P

Tumor type
Adenocarcinoma
Signet ring cell adenocarcinoma
Early gastric cancer
Malign neuroendocrine tumor

24
4
1
1

110
380
40
40

ns
<0.05*
ns
ns

Tumor histology
Intestinal
Diffuse

13
17

116
16

ns
ns

Tumor differentiation
Well
Moderately
Poorly

4
10
16

170
87
168

ns
ns
ns

Tumor class
T1
T2
T3
T4

1
2
9
18

40
89
159
268

ns
ns
<0.05*
<0.05*

Adjacent tissue invasion
Absent
Present

16
14

105
174

<0.05*

Lymph node metastases
N0
N1
N2
N3

7
14
8
1

114
145
173
40

ns
ns
ns
ns

Distant metastases
Absent
Present

10
20

128
152

ns
ns

TNM stage
IA
IB
II
IIIA
IIIB
IV

1
2
2
7
7
11

40
268
40
112
180
141

ns
ns
ns
ns
ns
ns

*: P < 0.05 (statistically significant), ns = nonsignificant.

Distant metastasis was not determined in 24 (80%)
patients by ultrasound examination before the operation,
but distant metastasis was seen in 6 (20%) patients. The
mean VEGF value of the patients who had no radiological
metastasis before the operation was 155 pg/mL. In patients
who had radiological metastasis before the operation, the
mean VEGF value was 89 pg/mL. There was no significant
correlation between these obtained VEGF values and
radiologically proven metastasis (P > 0.005).
The number of patients who had metastasis noted
during the operation was 10 (33.3%) and the number
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of patients who had no metastasis was 20 (66.7%). This
difference was not significant (P > 0.05).
Sixteen patients (53.3%) had invasion of adjacent
tissues and organs noted during the operation and the
mean VEGF level of these patients was 174 pg/mL; the
mean VEGF level of the 14 patients (46.7%) who had no
invasion was 105 pg/mL. This difference was statistically
significant (P < 0.05).
According to the differentiations of tumor types, 4
(13.3%) patients had well-differentiated tumors, 10 (33.3%)
patients moderately differentiated, and 16 (53.3%) were
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poorly differentiated. The mean VEGF levels were 170,
87, and 168 pg/mL, respectively, in the well-differentiated,
moderately differentiated, and poorly differentiated
tumors. There was no statistically significant correlation
between VEGF values and tumor differentiation (P > 0.05).
According to Lauren classification, 17 (56.7%) patients
had diffuse-type and 13 (43.3%) patients had intestinaltype gastric cancer in pathologic analysis of all gastric
cancers. The mean VEGF value of the patients who had
diffuse-type gastric cancer was 16 pg/mL and the mean
VEGF value of the patients who intestinal-type gastric
cancer was 116 pg/mL. This difference was not statistically
significant (P > 0.05).
When the 30 patients were examined in terms of the
depth of the tumor, 1 was T1 (3.3%), 2 were T2 (6.7%), 9
were T3 (30%), and 18 were T4 (60%). The mean VEGF
values of these groups were 40, 89, 159, and 268 pg/mL,
respectively. Differences between VEGF values and the
depth of the tumor were statistically significant (P < 0.05).
Distribution of patients according to stage of tumor,
lymph nodes in the pathology specimen, and VEGF
levels of each group is shown in Table 2. There were no
statistically differences between VEGF levels (P > 0.05).
4. Discussion
In 1971, Folkman suggested that solid tumor development
and metastasis formation depend on new vessels (11).
Based on this hypothesis, the role of angiogenesis has been
well recognized in the processes of tumor development,
infiltration, and metastasis formation. Tumor cells
must have a vascular structure that carries the required
oxygen and other micronutrients to their fields in order
to provide the unlimited growth and clearance of the
residual materials in their fields (12). While angiogenesis
is in balance within very strict rules in normal organisms,
angiogenesis in tumor tissue is uncontrolled and
immature (12). Serosal invasion, adjacent tissue invasion,
peritoneal dissemination, and metastasis are common in
gastric cancer. We examined the serum VEGF levels of the
patients in terms of clinicopathologic characteristics and
differences between healthy control groups in this study.
Several studies have shown that VEGF plays a key role
in angiogenesis in gastric cancer (13–15). In our study,
VEGF levels in the gastric cancer group were higher than
in the control group. There was no meaningful difference
statistically, but this may be due to the small size and
heterogeneity of our study. There was no contribution of
hemoglobin, AST, or ALT values in terms of staging and
prognosis in the preoperative period of our study, and
this has been shown in the literature as well. The mean of
these values in this study was within the normal limits, and
there was no correlation between clinical and pathological
features of the patients.

Although Dittrich et al. said that it is early to suggest
CEA levels as a reliable routine prognosis and treatment
parameter before and after the operation for gastric cancer
patients in their study (16), Gaspar et al. observed that
CEA levels increased when liver and peritoneal metastasis
appeared in gastric cancer (17). Ishigami et al. showed
that high levels of CEA depend on liver metastasis in
549 patients (18). A strong and statistically significant
correlation between CEA levels and high VEGF levels was
determined in our study. Yoshikawa et al. determined that
there is a relation between increased blood VEGF levels
and disease recurrence (19). When the biological role of
VEGF is considered in metastasis formation, high blood
CEA levels can provide information in terms of prognosis
before the operation.
Huang et al. did not find a difference between serums
VEGF levels of patients who had early-diagnosed gastric
cancer in their study, which consisted of 107 patients (20).
They used the Lauren classification of intestinal, diffuse,
and mixed types in the same study and did not find any
meaningful difference between intestinal and diffuse types.
However, they found that serum VEGF levels were higher
in the mixed type than in the other 2 groups. Salgado et
al. found that the tissue VEGF expression was higher in
diffuse-type than in intestinal-type gastric cancer (21).
Takahashi et al. found that tissue VEGF levels were higher
in the intestinal type in their study, where 38 of the patients
had diffuse-type and 51 had intestinal-type gastric cancer,
and they concluded that angiogenesis is more necessary
for metastasis in the intestinal type (22). There was no
significant difference between intestinal- and diffuse-type
gastric cancers according to serum VEGF levels in our
study.
Kitamura et al. showed that serum VEGF levels were
higher in patients who had serosal invasion, and there was
no relation between tumor depth and VEGF levels in their
study carried out in 281 patients (23). In our study, serum
VEGF levels in the patients who had serosal invasion were
higher. It is clear that tumors need vascularity to extend
out of serosa. For this reason, it is possible that the VEGF
level of tumors that do not extend to the serosa is lower.
Shi et al. did not determine a relation between VEGF
levels and tumor differentiation in the cancer tissue in their
study carried out in 281 patients (24). Du et al. determined
that increased VEGF values were seen when tumor
differentiation worsened in their study (12). Kitamura et
al. did not determine a significant relation between tissue
VEGF levels and tumor differentiation (23). There was
also no significant relation between serum VEGF levels
and tumor differentiation in our study. When tumor
types and serum VEGF levels were compared, statistically
significant high levels of VEGF were seen in signet ring cell
adenocarcinoma. Indeed, VEGF is associated with tumor
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invasion rather than differentiation. In signet ring cell
tumors, peritoneal implants, hematogenous metastasis,
and early recurrence are seen in most cases. Our study
also supports these findings. Maeda et al., and many other
researchers, showed that the higher levels in both serum
and tissue VEGF levels were associated with peritoneal,
hematogenous, and lymphatic metastasis (25).
The above comparisons between VEGF levels and
lymph node involvement come from Japan, where D1 and
D2 lymph node dissections have been precisely carried
out. The results from these studies clearly show that VEGF
is necessary for lymphatic metastasis. However, we found
no relation between lymph node involvement and serum
VEGF levels in our study. One of the reasons for this is that
palliative surgical procedures were chosen for the majority
of our patients because most of them were stage IIIB and
IV; therefore, complete lymph node dissections were not

conducted. The numbers of obtained lymph nodes were
low because the numbers of patients who had tumors in
early stages were low.
Serum VEGF levels in the gastric cancer group were
higher than in the control group in our study, but this
difference was not statistically significant. There was no
relation between the distribution of patients according to
the stage and serum VEGF values. This situation may have
resulted from the low number and the heterogeneity of the
patients.
In conclusion, in gastric cancer patients, serum VEGF
levels may provide additional prognostic information for
preoperative evaluation of invasion and tumor type. The
benefits of the clinical use of VEGF in choosing treatment
methods and antiangiogenesis treatments will become
clearer after results of further clinical studies are obtained
with an increased number of patients.
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